A purported leak containing marketing materials for a new gaming laptop from Lenovo suggests the company may debut a Windows 11 PC with a horizontal rollable display that expands out to an ultrawide 21:9 screen ratio.
Don’t miss any of our…
Shoulder conditions and disorders are commonly experienced musculoskeletal pain conditions and have a prevalence (20.9%) comparable to back (26.9%) and neck pain (20.6%).1 For example, in a 15-year population-based study in the…
In 1987 Faith Evans, who has died aged 83, set about realising the concept of a small literary agency with a distinct identity, akin to the list or imprint of a publisher. It would focus on ideas and the kind of books that would enable her to…
This month, as Paltrow began promoting her new film Marty Supreme alongside Timothée Chalamet, the star has been spotted in a few of her minimalist designs on the step and repeat. Because why wouldn’t she be her own muse? She is her best…
A major burst of solar material is on track to reach Earth soon, according to an alert from NOAA’s Space Weather Prediction Center. Forecasters say a coronal mass ejection, an enormous release of plasma and magnetic energy from the Sun’s…
SAVE $100: As of Dec. 9, get the Blink Outdoor 4 + Mini 2 bundle for $69.98 at Amazon, down from its usual price of $169.98. That’s a discount of 59%.
In an individual-patient pooled analysis reported in the Journal of Clinical Oncology, Raimondi et al found that neoadjuvant treatment with dual CTLA-4/PD-(L)1 immune checkpoint inhibitors (ICIs) was associated with higher pathologic response rates vs perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) in patients with deficient mismatch repair (dMMR)/microsatellite instability–high (MSI-H) resectable gastroesophageal adenocarcinoma.
Study Details
The study included 197 patients from seven clinical trials who received: neoadjuvant dual CTLA-4/PD-(L)1 ICIs with or without surgery, perioperative FLOT and surgery, and surgery with or without older perioperative/adjuvant chemotherapy regimens. Primary outcome measures included pathologic complete response and major pathologic response.
Key Findings
Among the 197 patients, 49 received ICIs, 27 received FLOT, 33 received surgery alone, and 88 received older chemotherapy regimens.
Among 69 patients who underwent surgery after ICIs or FLOT, those receiving ICIs had significantly higher pathologic complete response rates (61.9% vs 3.7%; odds ratio [OR] = 54.8; P = .002) and major pathologic response rates (78.6% vs 10.0%; OR = 39.3; P < .001), as well as higher rates of pN0 (OR = 4.2; P = .015) and pT0-2 (OR = 16.4; P < .001).
No significant differences in event-free survival or overall survival were observed.
Among all patients, residual nodal disease (ypN1) or ypT4 status after neoadjuvant ICIs or FLOT and an absence of pathologic response were associated with poorer progression-free and overall survival.
The investigators, including corresponding author Filippo Pietrantonio, MD, of the Department of Medical Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy, concluded: “In resectable dMMR/MSI-H [gastroesophageal adenocarcinoma], neoadjuvant ICIs significantly increase pathologic response and downstaging vs FLOT, with comparable [event-free survival/overall survival] with surgery with or without chemotherapy. The higher proportion of ypN0 and lack of ypT4 after neoadjuvant ICIs vs FLOT should drive preoperative treatment choices in clinical high-risk disease. The high proportion of [pathological complete responses/major pathological responses] with ICIs provides rationale for exploring organ-sparing surgery or nonoperative management.”
Raimondi A, et al: J Clin Oncol 43:3457-3467, 2025.
